Skip to main content
SpringerLink
Log in

The Importance of AFP in Liver Transplantation for HCC

  • Review Article
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Introduction

The most common biomarker for HCC is serum alpha-fetoprotein (AFP). AFP is used for screening and diagnosing HCC, and also, it is used for predicting prognosis and monitoring the response to treatment.

Discussion

AFP secretion is associated with poor tumor histologic grade and aggressive tumor biological behavior. The risk of dropout on the waiting list for liver transplantation and the risk of tumor recurrence after liver transplantation are associated with high AFP serum levels. Therefore, using AFP levels for selecting patients to include on the liver transplantation waiting lists is critical. It is also known that a low AFP serum level before liver transplantation has limited informative value, but high AFP levels prior to liver transplantation indicate a higher risk for HCC recurrence.

Conclusion

AFP’s performance as a screening, diagnostic, and prognostic marker for HCC is not ideal, but it is the most frequently used biomarker in the management of HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AFP:

alpha‐Fetoprotein

HCC:

Hepatocellular carcinoma

CT:

Computerized tomography

MRI:

Magnetic Resonance Imaging

LT:

Liver transplantation

References

  1. Terentiev AA, Moldogazieva NT. Alpha-fetoprotein: a renaissance. Tumour Biol. 2013;34:2075–91.

    CAS  Google Scholar 

  2. Khan A, Asmaa I, Edward L, Waked I, Taylor-Robinson SD. Diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2009;15(11):1301–14. https://doi.org/10.3748/wjg.15.1301.

    Article  Google Scholar 

  3. Zhao YJ, Ju Q, Li GC. Tumor markers for hepatocellular carcinoma. Mol Clin Oncol. 2013;1:593–8.

    CAS  Google Scholar 

  4. Kajiyama Y, Tian J, Locker J. Characterization of distant enhancers and promoters in the albumin-alpha-fetoprotein locus during active and silenced expression. J Biol Chem. 2006;281:30122–31.

    CAS  Google Scholar 

  5. Li MS, Li PF, He SP, Du GG, Li G. The promoting molecular mechanism of alpha-fetoprotein on the growth of human hepatoma Bel7402 cell line. World J Gastroenterol. 2002;8:469–75.

    CAS  Google Scholar 

  6. .

  7. Laderoute MP, Pilarski LM. The inhibition of apoptosis by alpha-fetoprotein (AFP) and the role of AFP receptors in anti-cellular senescence. Anticancer Res. 1994;14:2429–38.

    CAS  Google Scholar 

  8. Toder V, Blank M, Gleicher N, Nebel L. Immunoregulatory mechanisms in pregnancy. II. Further characterization of suppressor lymphocytes induced by alpha-fetoprotein in lymphoid cell cultures. JClin Lab Immunol. 1983;11:149–54.

    CAS  Google Scholar 

  9. Wang XW, Xu B. Stimulation of tumor-cell growth by alpha-fetoprotein. Int J Cancer. 1998;75:596–9.

    CAS  Google Scholar 

  10. Wang XW, Xie H. Alpha-fetoprotein enhances the proliferation of human hepatoma cells in vitro. Life Sci. 1999;64:17–23.

    CAS  Google Scholar 

  11. Shan YF, Huang YL, Xie YK, et al. Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and alpha-fetoprotein expression status. Med Oncol. 2011;28:1012–6.

    CAS  Google Scholar 

  12. Meng W, Li X, Bai Z, Li Y, Yuan J, Liu T, et al. Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell. PLoS One. 2014;9:e90660.

    Google Scholar 

  13. Mizejewski GJ. Levels of alpha-fetoprotein during pregnancy and early infancy in normal and disease states. Obstet Gynecol Surv. 2003;58:804–26.

    Google Scholar 

  14. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alphafetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol. 2001;34:570–5.

    CAS  Google Scholar 

  15. Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gammacarboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137:110–8.

    CAS  Google Scholar 

  16. Di Bisceglie AM, Sterling RK, Chung RT, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43:434–41.

    Google Scholar 

  17. Yang SW, Kim GH, Chung JW, Sohn HR, Lee SS, Hong S, et al. Prediction of risk for hepatocellular carcinoma by response of serum alpha-fetoprotein to entecavir therapy. J Gastroenterol Hepatol. 2015;30:1175–82.

    CAS  Google Scholar 

  18. Shim JJ, Kim JW, Lee CK, Jang JY, Kim BH. Oral antiviral therapy improves the diagnostic accuracy of alpha-fetoprotein levels in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2014;29:1699–705.

    CAS  Google Scholar 

  19. Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101:513–23.

    CAS  Google Scholar 

  20. Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34:603–5.

    CAS  Google Scholar 

  21. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417–22.

    Google Scholar 

  22. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomark Prev. 2012;21:793–9.

    Google Scholar 

  23. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

    Google Scholar 

  24. Omata M, Cheng A-L, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317–70.

    Google Scholar 

  25. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458–68.

    Google Scholar 

  26. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358–80.

    Google Scholar 

  27. Bruix J, Cheng AL, Meinhardt G, Nakajima K, De SY, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol. 2017;67:999–1008.

    CAS  Google Scholar 

  28. Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and pre-cision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018;15:599–616.

    Google Scholar 

  29. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302–8.

    CAS  Google Scholar 

  30. Yang SH, Suh KS, Lee HW, et al. A revised scoring system utilizing serum alpha-fetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery. 2007;141:598–609.

    Google Scholar 

  31. Kwon C, Kim DJ, Han YS, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis. 2007;25:313–9.

    Google Scholar 

  32. Zheng SS, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation. 2008;85:1726–32.

    CAS  Google Scholar 

  33. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant. 2008;8:2547–57.

    CAS  Google Scholar 

  34. Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, et al. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015;62:158–65.

    CAS  Google Scholar 

  35. Vibert E, Azoulay D, Hoti E, Iacopinelli S, Samuel D, Salloum C, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010;10:129–37.

    CAS  Google Scholar 

  36. Merani S, Majno P, Kneteman NM, Berney T, Morel P, Mentha G, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011;55:814–9.

    CAS  Google Scholar 

  37. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including ɑ-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012;143:986–94.

    CAS  Google Scholar 

  38. Lai Q, Avolio AW, Manzia TM, et al. Combination of biological and morphological parameters for the selection of patients with hepatocellular carcinoma waiting for liver transplantation. Clin Transplant. 26:E125–31.

  39. Vitale A, Volk ML, De Feo TM, Liver Transplantation North Italy Transplant program (NITp) working group, et al. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list. J Hepatol. 2014;60:290–7.

    Google Scholar 

  40. Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, Agostini A, et al. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score. Ann Surg. 2016;264:787–96.

    Google Scholar 

  41. Sapisochin G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: a prospective validation study. Hepatology. 2016;64:2077–88.

    Google Scholar 

  42. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, Guarrera JV, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg. 2017;265:557–64.

    Google Scholar 

  43. Lai Q, Vitale A, Iesari S, et al; European Hepatocellular Cancer Liver Transplant Study Group. Intention-to-treat survival benefit of liver transplantation in patients with hepatocellular cancer. Hepatology. 2017;66:1910–1919.

  44. Mazzaferro V, Sposito C, Zhou J, Pinna AD, de Carlis L, Fan J, et al. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018;154:128–39.

    Google Scholar 

  45. Han K, Tzimas GN, Barkun JS, Metrakos P, Tchervenkov JI, Hilzenrat N, et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol. 2007;21:39–45.

    Google Scholar 

  46. Grąt M, Krasnodębski M, Patkowski W, Wronka KM, Masior Ł, Stypułkowski J, et al. Relevance of pretransplant ɑ-fetoprotein dynamics in liver transplantation for hepatocellular cancer. Ann Transplant. 2016;21:115–24.

    Google Scholar 

  47. Piñero F, Tisi Baña M, de Ataide EC, Latin American Liver Research, Education and Awareness Network (LALREAN). Liver 2228 GALLE, et al. Transplantation for hepatocellular carcinoma: evaluation of the alpha-fetoprotein model in a multicenter cohort from Latin America. Liver Int. 2016;36:1657–67.

    Google Scholar 

  48. Notarpaolo A, Layese R, Magistri P, et al. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC. J Hepatol. 2017;66:552–9.

    Google Scholar 

  49. Mehta N, Dodge JL, Roberts JP, Yao FY. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018;18:1206–13.

    CAS  Google Scholar 

  50. Hong G, Suh K-S, Suh S-W, Yoo T, Kim H, Park MS, et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64:852–9.

    CAS  Google Scholar 

  51. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, et al. Liver transplantation for hepatocellular carcinoma: management after the transplant. Am J Transplant. 2019.

  52. Foerster F, Hoppe-Lotichius M, Vollmar J, Marquardt JU, Weinmann A, Wörns MA, et al. Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. United Eur Gastroenterol J. 2019;7(6):838–49.

    Google Scholar 

  53. Kondili LA, Lala A, Gunson B, Hubscher S, Olliff S, Elias E, et al. Primary hepatocellular cancer in the explanted liver: outcome of transplantation and risk factors for HCC recurrence. Eur J Surg Oncol. 2007 [cited2019Sep3];33(7):868–73.

    CAS  Google Scholar 

  54. Agopian V G , Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: Analysis of 865 consecutive liver transplant recipients. In: Journal of the American College of Surgeons. Elsevier Inc.;2015. p.416–27.

  55. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol. 2017;3:493–500.

    Google Scholar 

  56. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68:723.

    Google Scholar 

  57. Ince V, Akbulut S, Otan E, Ersan V, Karakas S, Sahin TT, et al. Liver transplantation for hepatocellular carcinoma: malatya experience and proposals for expanded criteria [published correction appears in J Gastrointest Cancer. 2020 Jul 8]. J Gastrointest Cancer. 2020;51(3):998–1005. https://doi.org/10.1007/s12029-020-00424-w.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Liver Transplantation Institute, Inonu University, 44315, Malatya, Turkey

    Fatih Özdemir & Adil Baskiran

Authors
  1. Fatih Özdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adil Baskiran
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Fatih Ozdemir and Adil Baskiran wrote and revised the article.

Corresponding author

Correspondence to Fatih Özdemir.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Özdemir, F., Baskiran, A. The Importance of AFP in Liver Transplantation for HCC. J Gastrointest Canc 51, 1127–1132 (2020). https://doi.org/10.1007/s12029-020-00486-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00486-w

Keywords

Search

Navigation